Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: This research's comprehensive review and meta-analysis seek to offer additional non-invasive techniques for diagnosing and monitoring liver fibrosis, thereby serving as a dependable resource for clinical practice and scientific investigation.
Methods: To find pertinent research on the use of serum YKL-40 levels in liver fibrosis patients, databases including PubMed, Web of Science, WILEY ONLINE LIBRARY, Scopus, Embase, Cochrane Library, Science Direct, CNKI, Wanfang Data, VIP Information, and the China Biology Medicine Library System were searched. The search was conducted up to May 2024.
Results: In studies comparing serum YKL-40 levels in patients with hepatic fibrosis and controls, the overall combined difference was 1.37 (0.66, 2.08), with the Chinese subgroup showing high heterogeneity, while the Egyptian study did not show heterogeneity. A total of 17 studies, including 2554 patients, were included. The combined sensitivity for diagnosing advanced fibrosis and severe fibrosis was 0.80 and 0.78 respectively, with specificities of 0.88 and 0.82. The AUC for advanced fibrosis and severe fibrosis were 0.91 and 0.87 respectively.
Conclusion: Serum YKL-40 shows potential value in diagnosis of liver fibrosis, but further clinical research is needed to confirm and improve its utility.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12319455 | PMC |
| http://dx.doi.org/10.18502/ijph.v54i5.18629 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Comparison of Novel Serum Markers of Liver Health in Adolescents With Metabolic Dysfunction-Associated Steatotic Liver Disease.
J Cell Mol Med
August 2025
Section of Gastroenterology, Hepatology, and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Several non-invasive biomarkers for paediatric metabolic dysfunction-associated steatotic liver disease (MASLD) have been reported, but no prior studies directly compared multiple protein or microRNA (miRNA) markers of liver health in adolescents with and without MASLD and determined which serum markers are associated with liver histopathological features. We measured 6 serum protein and 4 miRNA candidates in 3 groups of participants: 23 with obesity and biopsy-proven MASLD, 24 controls with obesity (Ob) and 24 controls with normal weight (NW). The MASLD group had higher median values for cytokeratin 18 (CK-18, 8.
View Article and Find Full Text PDFCerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.
J Neurol
August 2025
Centre de Ressources Biologiques Lorrain (CRBL), Centre Hospitalier Régional Universitaire de Nancy, Nancy, Grand Est, France.
Background: Platform therapies, such as dimethylfumarate, teriflunomide, and interferons beta, are insufficient to control relapsing-remitting multiple sclerosis in many patients. Having biomarkers available to stratify patients as good or poor responders before starting treatment would represent a considerable advance.
Methods: We tested serum and cerebrospinal fluid (CSF) levels of chitinase 3-like 1 (c and s-CHI3L1), soluble trigger receptor expressed on myeloid cells (sTREM2) and neuronal pentraxin 2 (NPTX2), and CSF levels of neurofilament light chains and of interleukin-6 (c-IL6) collected before treatment start in 70 patients in Eastern France.
Neuroglial biomarkers in autoimmune encephalitis: advances in diagnosis, prognosis, and pathophysiological insights.
Neurol Sci
August 2025
Department of Human Neurosciences, Sapienza University, Viale dell'Università, 30, Rome, 00185, Italy.
Autoimmune encephalitis (AE) presents with a diverse spectrum of neuropsychiatric symptoms, often leading to diagnostic challenges and delays in treatment. Neuroglial biomarkers may improve AE diagnosis, disease monitoring, and prognostication. This review examines the diagnostic and prognostic value of fluid biomarkers in AE, focusing on markers of neuroaxonal damage, synaptic dysfunction, astroglial activation, and amyloid metabolism.
View Article and Find Full Text PDFEstablishment of a YKL-40 time-resolved Immunoassay and Application in Diabetic Kidney Disease.
J Fluoresc
August 2025
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
To develop a highly sensitive, wide-linear-range time-resolved fluorescence immunoassay (TRFIA) to detect serum YKL-40 and to measure its concentrations in patients with diabetic kidney disease (DKD). A double-antibody sandwich method was employed to establish the YKL-40 TRFIA, which utilizes two antibodies targeting distinct epitopes on the YKL-40 antigen (a coating antibody and a labeled antibody). The assay's linearity, sensitivity, accuracy, specificity, and recovery rate were evaluated.
View Article and Find Full Text PDFSerum YKL-40 Levels as a Non-Invasive Potential Biomarker for Liver Fibrosis Patients: A Systematic Review and Meta-Analysis.
Iran J Public Health
May 2025
Department of Integrated Traditional Chinese and Western Medicine Hepatology, Changzhou Third People's Hospital, Changzhou City, Jiangsu Province, 213000, China.
Background: This research's comprehensive review and meta-analysis seek to offer additional non-invasive techniques for diagnosing and monitoring liver fibrosis, thereby serving as a dependable resource for clinical practice and scientific investigation.
Methods: To find pertinent research on the use of serum YKL-40 levels in liver fibrosis patients, databases including PubMed, Web of Science, WILEY ONLINE LIBRARY, Scopus, Embase, Cochrane Library, Science Direct, CNKI, Wanfang Data, VIP Information, and the China Biology Medicine Library System were searched. The search was conducted up to May 2024.